Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Biol Chem ; 295(30): 10092-10111, 2020 07 24.
Artigo em Inglês | MEDLINE | ID: mdl-32482892

RESUMO

Aortic dissection is a life-threatening aortopathy involving separation of the aortic wall, whose underlying mechanisms are still incompletely understood. Epidemiological evidence suggests that unsaturated fatty acids improve cardiovascular health. Here, using quantitative RT-PCR, histological analyses, magnetic cell sorting and flow cytometry assays, and MS-based lipidomics, we show that the activity of a lipid-metabolizing enzyme, secreted phospholipase A2 group V (sPLA2-V), protects against aortic dissection by endogenously mobilizing vasoprotective lipids. Global and endothelial cell-specific sPLA2-V-deficient mice frequently developed aortic dissection shortly after infusion of angiotensin II (AT-II). We observed that in the AT-II-treated aorta, endothelial sPLA2-V mobilized oleic and linoleic acids, which attenuated endoplasmic reticulum stress, increased the expression of lysyl oxidase, and thereby stabilized the extracellular matrix in the aorta. Of note, dietary supplementation with oleic or linoleic acid reversed the increased susceptibility of sPLA2-V-deficient mice to aortic dissection. These findings reveal an unexplored functional link between sPLA2-driven phospholipid metabolism and aortic stability, possibly contributing to the development of improved diagnostic and/or therapeutic strategies for preventing aortic dissection.


Assuntos
Aorta/metabolismo , Dissecção Aórtica/metabolismo , Estresse do Retículo Endoplasmático , Fosfolipases A2 do Grupo V/metabolismo , Fosfolipídeos/metabolismo , Dissecção Aórtica/induzido quimicamente , Dissecção Aórtica/genética , Angiotensina II/efeitos adversos , Angiotensina II/farmacologia , Animais , Aorta/patologia , Modelos Animais de Doenças , Fosfolipases A2 do Grupo V/genética , Ácido Linoleico/genética , Ácido Linoleico/metabolismo , Camundongos , Camundongos Knockout , Ácido Oleico/genética , Ácido Oleico/metabolismo , Fosfolipídeos/genética
2.
Int Heart J ; 59(5): 1174-1179, 2018 Sep 26.
Artigo em Inglês | MEDLINE | ID: mdl-30158382

RESUMO

Angiogenesis inhibitors, such as sorafenib and axitinib, which target vascular endothelial growth factor (VEGF) signaling, are widely used for renal cell carcinoma, including metastasis. In this study, we report a case of cardiovascular adverse events of aortic dissection and cardiac dysfunction during treatment with sorafenib and axitinib for metastatic renal cell carcinoma. A 66-year-old man had been administered sorafenib for 2 years after nephrectomy due to renal cell carcinoma. To control the progression of metastatic lung tumor, axitinib was started after sorafenib for four years. During the treatment, angiotensin II type 1 receptor blockers and Ca antagonists were used to strictly control the axitinib-induced hypertension and proteinuria. Aortic dissection and cardiac dysfunction occurred coincidentally. Considering the critical role of VEGF signaling in the homeostasis of the cardiovascular system, we speculated that the long-term use of axitinib and sorafenib directly influenced the initiation of aortic dissection and cardiac dysfunction. Although the precise mechanisms underlying the aortic dissection and cardiac dysfunction induced by angiogenesis inhibition are still elusive, onco-cardiologists and oncologists should pay careful attention to cardiovascular toxicity and complications in patients with cancer, particularly patients undergoing long-term cancer treatment.


Assuntos
Inibidores da Angiogênese/efeitos adversos , Dissecção Aórtica/induzido quimicamente , Carcinoma de Células Renais/tratamento farmacológico , Cardiopatias/induzido quimicamente , Imidazóis/efeitos adversos , Indazóis/efeitos adversos , Neoplasias Renais/tratamento farmacológico , Neoplasias Pulmonares/secundário , Niacinamida/análogos & derivados , Compostos de Fenilureia/efeitos adversos , Idoso , Dissecção Aórtica/complicações , Axitinibe , Carcinoma de Células Renais/patologia , Carcinoma de Células Renais/cirurgia , Cardiopatias/complicações , Cardiopatias/fisiopatologia , Humanos , Imidazóis/administração & dosagem , Imidazóis/uso terapêutico , Indazóis/administração & dosagem , Indazóis/uso terapêutico , Neoplasias Renais/patologia , Neoplasias Renais/cirurgia , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/patologia , Masculino , Metástase Neoplásica , Niacinamida/administração & dosagem , Niacinamida/efeitos adversos , Niacinamida/uso terapêutico , Compostos de Fenilureia/administração & dosagem , Compostos de Fenilureia/uso terapêutico , Inibidores de Proteínas Quinases/efeitos adversos , Inibidores de Proteínas Quinases/uso terapêutico , Sorafenibe , Fator A de Crescimento do Endotélio Vascular/efeitos dos fármacos , Fator A de Crescimento do Endotélio Vascular/metabolismo
4.
Arterioscler Thromb Vasc Biol ; 37(3): 401-410, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-28062500

RESUMO

Human abdominal aortic aneurysm (AAA) pathophysiology is not yet completely understood. In conductance arteries, the insoluble extracellular matrix, synthesized by vascular smooth muscle cells, assumes the function of withstanding the intraluminal arterial blood pressure. Progressive loss of this function through extracellular matrix proteolysis is a main feature of AAAs. As most patients are now treated via endovascular approaches, surgical AAA specimens have become rare. Animal models provide valuable complementary insights into AAA pathophysiology. Current experimental AAA models involve induction of intraluminal dilation (nondissecting AAAs) or a contained intramural rupture (dissecting models). Although the ideal model should reproduce the histological characteristics and natural history of the human disease, none of the currently available animal models perfectly do so. Experimental models try to represent the main pathophysiological determinants of AAAs: genetic or acquired defects in extracellular matrix, loss of vascular smooth muscle cells, and innate or adaptive immune response. Nevertheless, most models are characterized by aneurysmal stabilization and healing after a few weeks because of cessation of the initial stimulus. Recent studies have focused on ways to optimize existing models to allow continuous aneurysmal growth. This review aims to discuss the relevance and recent advances of current animal AAA models. VISUAL OVERVIEW: An online visual overview is available for this article.


Assuntos
Aorta Abdominal , Aneurisma da Aorta Abdominal , Dissecção Aórtica , Pesquisa Translacional Biomédica , Dissecção Aórtica/induzido quimicamente , Dissecção Aórtica/metabolismo , Dissecção Aórtica/patologia , Dissecção Aórtica/fisiopatologia , Animais , Aorta Abdominal/metabolismo , Aorta Abdominal/patologia , Aorta Abdominal/fisiopatologia , Aneurisma da Aorta Abdominal/induzido quimicamente , Aneurisma da Aorta Abdominal/metabolismo , Aneurisma da Aorta Abdominal/patologia , Aneurisma da Aorta Abdominal/fisiopatologia , Modelos Animais de Doenças , Humanos , Especificidade da Espécie
5.
Aktuelle Urol ; 45(2): 132-4, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24700069

RESUMO

A 48-year-old male presented with para-aortic lymph node metastases after surgical resection of a clear cell renal cell carcinoma. After first-line treatment with interferon alpha-2b, he was started on pazopanib and lapatinib. Blood pressure was well controlled with temocapril and amlodipine. Treatment had to be stopped 4 years and 8 months after initiation due to overt proteinuria. Then, sunitinib was started as third-line treatment. During the second cycle of sunitinib, he died due to a Stanford type A aortic dissection. Acute aortic dissection could be an adverse event associated with the long-term use of antiangiogenic tyrosine kinase inhibitors.


Assuntos
Inibidores da Angiogênese/efeitos adversos , Aneurisma Aórtico/induzido quimicamente , Aneurisma Aórtico/patologia , Dissecção Aórtica/induzido quimicamente , Dissecção Aórtica/patologia , Carcinoma de Células Renais/tratamento farmacológico , Indóis/efeitos adversos , Neoplasias Renais/tratamento farmacológico , Proteínas Tirosina Quinases/antagonistas & inibidores , Pirróis/efeitos adversos , Doença Aguda , Inibidores da Angiogênese/administração & dosagem , Carcinoma de Células Renais/patologia , Quimioterapia Adjuvante , Evolução Fatal , Humanos , Indóis/administração & dosagem , Neoplasias Renais/patologia , Assistência de Longa Duração , Metástase Linfática/patologia , Masculino , Pessoa de Meia-Idade , Proteínas Tirosina Quinases/administração & dosagem , Pirróis/administração & dosagem , Sunitinibe , Tomografia Computadorizada por Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA